Jonathan Cebon
Director, Jonathan Cebon Lab
Jonathan Cebon Lab
Ludwig Institute for Cancer Research
Australia
Biography
My overall aims are to improve outcomes for cancer patients and contribute to a dynamic translational and clinical research community. As a physician–scientist, I have longstanding experience in the clinical application of novel immunotherapies for the treatment of melanoma. I have led numerous Phase I and II clinical trials across a broad portfolio of clinical and translational projects involving cytokines, peptide and protein vaccines, as well as targeted therapies including development of BRAF and MEK inhibitors. Over 20 years I have developed integrated clinical and laboratory teams focused on understanding immune responses against cancer and exploring new cancer therapies based on this knowledge. More recently, new insights into tumor resistance have shown that it is also critical to understand the biology of cancer plasticity to counter the mechanisms that underpin escape from immune control. My research brings these elements together with the intention of achieving greater clinical benefit.
Research Interest
melanoma cell biology and immunology
Publications
-
Luft, Thomas, et al. "Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E 2 regulates the migratory capacity of specific DC subsets." Blood 100.4 (2002): 1362-1372.
-
Stanley, Edouard, et al. "Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology." Proceedings of the National Academy of Sciences 91.12 (1994): 5592-5596.
-
Flaherty, Keith T., et al. "Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations." New England Journal of Medicine 367.18 (2012): 1694-1703.
